Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoTeT: Molnupiravir for Mild COVID-19
NCT05459532Phase 3Completed
- Sponsor
- University of the Witwatersrand
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Molnupiravir with Placebo (2 arms). Primary endpoints: Effectiveness of molnupiravir compared to placebo in preventing severe disease progression at 29 Days and Safety of molnupiravir at 29 Days. Started Aug 2022; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05459532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05459532.